ScanTrail
A patient companion app that walks a newly diagnosed cancer patient through their upcoming diagnostic workup, explaining what each test is for, what the doctor is looking for, and roughly what to expect in cost and time — built around the idea that not every patient needs every test.
Newly diagnosed adult cancer patients and their family caregivers trying to make sense of a fast, scary queue of tests
- Plain-English test explainer tuned to the specific cancer type (e.g., glioma, breast, prostate) with visuals and 'why this test, why now' reasoning
- Question prompts to bring to the care team (e.g., 'Is the genomic panel needed before we decide on surgery?')
- Cost/time tracker and prep checklists (fasting, transport, recovery) for each scheduled test
- Family-shared view so a caregiver can see the full schedule and help coordinate
The underlying research just showed that AI can safely skip 55% of diagnostic burden for glioma patients without losing accuracy — a striking signal that the standard 'do everything' workup is overdue for a rethink, and patients are the ones most under-served by that rethink.
Cancer patient navigation is a validated need — Springer systematic review confirms impact on access and outcomes, and 197+ cancer apps crowd the iOS store with Outcomes4Me as an award-winning incumbent serving newly diagnosed patients.Patient Navigation in Cancer Treatment: A Systematic Review ↗197+ Best Cancer Treatment App Apps for iPhone (2026) | Free & Paid ↗
Incumbents (Outcomes4Me, Noona, myOnco360) focus on treatment guidance, clinical trials, and medication management — none I found specifically walks patients through the *diagnostic workup queue* with cost/time expectations per test, leaving a real, narrow gap.Outcomes4Me Reviews and Pricing 2026 | F6S ↗5 Best Cancer Support Apps for Patients in 2026 ↗
Leading patient-side competitor Outcomes4Me is free, cancer patients face significant financial toxicity, and there is no obvious consumer WTP signal; would likely need B2B2C sell to health systems or payers — a longer, harder sale.Outcomes4Me - Welcome ↗Outcomes4Me Reviews and Pricing 2026 | F6S ↗
AI-driven diagnostic optimization in oncology is a sustained research direction (multiple glioma AI reviews and the broader companion-diagnostic market growing 9–12% CAGR), but pushing test-skipping advice to patients invites clinical/regulatory friction that limits long runway.Artificial Intelligence in Glioma Diagnosis: A Narrative Review ↗
Building a static test-explanation library is straightforward, but the differentiated value prop (recommending which tests to skip) requires validated clinical models — and the underlying SAGEAgent-style research is pre-clinical, so the AI-driven guidance layer is hard to ship responsibly.Artificial Intelligence in Glioma Diagnosis: A Narrative Review ↗Top 10 Cancer Support Apps to Download - Together4Cancer ↗